The Company

RetinalGeniX Technologies, Inc. is an emerging medical device company focused on commercializing the next generation of cost-effective, ultra-wide imaging technologies to examine the periphery of the retina, at up to a 200° field of view, to detect early signs of diabetic retinopathy and maculopathy without having to dilate a patient's pupil. There is a need for a simpler and more affordable device and method that allows for simplified but accurate imaging of a person’s retina to detect symptoms of diabetic retinopathy.

Diabetes is a growing epidemic in the United States and abroad. The American Diabetes Association (ADA) reports that more than 23 million children and adults in the United States are living with the disease (about 8% of the population), roughly 7 million of whom are unaware of their condition. Multiply 23 million by three and the probable number of people in the U.S. with pre-diabetes is 69 million.

The World Diabetes Foundation estimates that there will be more than 438 million people worldwide with diabetes by 2030.  The Centers for Disease Control and Prevention estimates as many as 110 million Americans will have diabetes by 2050, equaling one-third of the U.S. population.

One of the effects of diabetes is retinopathy, a degenerative disease of the retina, which is the layer of receptors in the eyes that receive light and pass the signals to the brain via the optic nerve.  As the retina degenerates, patients experience loss of vision due to bleeding, retinal detachment, and other factors.  Left untreated, diabetic retinopathy can lead to permanent blindness.  Detected early and treated effectively, however, retinopathy and maculopathy can be stopped so that vision can be maintained. The proliferation of tools making early diagnosis easy and inexpensive is a critical factor in broadening care.